Aclaris Therapeutics, Inc. Balance Sheet
ACRS|9 years of annual SEC 10-K data (FY2017-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 9 fiscal years. All figures from audited SEC 10-K filings.
Aclaris Therapeutics, Inc. had $160M in total assets and $103M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.0M | $24.6M | $39.9M | $45.3M | $27.3M | $22.1M | - | $168.0M | $30.2M |
| Accounts Receivable | - | $318.0K | $298.0K | $484.0K | $623.0K | $772.0K | $704.0K | $563.0K | $481.0K |
| Inventory | - | - | - | - | - | - | - | $791.0K | - |
| Current Assets | $96.3M | $126.0M | $128.9M | $231.6M | $205.0M | $57.5M | $83.8M | $179.5M | $200.2M |
| PP&E (Net) | $761.0K | $1.0M | $1.6M | $1.1M | $1.3M | $1.7M | $2.5M | $2.3M | $2.2M |
| Goodwill | - | - | - | - | - | - | - | $18.5M | $18.5M |
| Total Assets | $160.5M | $220.3M | $197.4M | $254.6M | $251.2M | $70.8M | $98.3M | $275.6M | $243.5M |
| Current Liabilities | $28.6M | $31.6M | $31.0M | $21.9M | $22.9M | $14.9M | $22.4M | $27.3M | $12.8M |
| Total Debt | - | - | - | - | - | $10.7M | - | $29.9M | - |
| Shareholders' Equity | $103.1M | $157.2M | $197.6M | $197.6M | $197.3M | $215.1M | $225.3M | $215.1M | $92.5M |